Korro Bio, Inc.
KRROHeld by 6 specialist biotech funds
High Convergence6 funds opened new positions. Next phase2 readout (KRRO-121): Aug 2027. Short interest: 12.7% of float.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.